Comparative Pharmacology
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DIMETANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ACUVUE THERAVISION WITH KETOTIFEN versus DIMETANE.
ACUVUE THERAVISION WITH KETOTIFEN vs DIMETANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketotifen is a selective histamine H1-receptor antagonist and mast cell stabilizer that inhibits the release of inflammatory mediators such as histamine and leukotrienes from mast cells.
Dimetane (brompheniramine) is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptor sites, preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also has anticholinergic and sedative properties.
One drop in each affected eye twice daily (approximately 8 hours apart) as needed. The lens should be removed prior to instillation and can be reinserted after at least 10 minutes.
1-2 tablets (4-8 mg chlorpheniramine maleate) orally every 4-6 hours, not to exceed 12 tablets (48 mg) in 24 hours.
None Documented
None Documented
12 hours (terminal elimination half-life; clinical context: twice-daily dosing needed for continuous effect).
Terminal elimination half-life is approximately 12-15 hours in adults, necessitating twice-daily or three-times-daily dosing for continuous effect.
Renal (approximately 50% as unchanged drug, 30% as metabolites); biliary/fecal elimination accounts for <10%.
Primarily renal excretion of metabolites, with approximately 50% of a dose excreted in urine as unchanged drug and metabolites; biliary/fecal excretion is minor (< 10%).
Category A/B
Category C
Antihistamine / Mast Cell Stabilizer
Antihistamine